U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C27H29NO11.ClH
Molecular Weight 579.98
Optical Activity UNSPECIFIED
Defined Stereocenters 6 / 6
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DOXORUBICIN HYDROCHLORIDE

SMILES

Cl.[H][C@@]1(C[C@H](N)[C@H](O)[C@H](C)O1)O[C@H]2C[C@@](O)(CC3=C(O)C4=C(C(=O)C5=C(OC)C=CC=C5C4=O)C(O)=C23)C(=O)CO

InChI

InChIKey=MWWSFMDVAYGXBV-RUELKSSGSA-N
InChI=1S/C27H29NO11.ClH/c1-10-22(31)13(28)6-17(38-10)39-15-8-27(36,16(30)9-29)7-12-19(15)26(35)21-20(24(12)33)23(32)11-4-3-5-14(37-2)18(11)25(21)34;/h3-5,10,13,15,17,22,29,31,33,35-36H,6-9,28H2,1-2H3;1H/t10-,13-,15-,17-,22+,27-;/m0./s1

HIDE SMILES / InChI
Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula C27H29NO11
Molecular Weight 543.5193
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 6 / 6
E/Z Centers 0
Optical Activity UNSPECIFIED

Approval Year

Unknown
86413
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:19:48 UTC 2023
Edited
by admin
on Fri Dec 15 15:19:48 UTC 2023
Record UNII
82F2G7BL4E
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DOXORUBICIN HYDROCHLORIDE
EMA EPAR   EP   MART.   ORANGE BOOK   USP   USP-RS   VANDF   WHO-DD   WHO-IP  
Common Name English
IMX-110 COMPONENT DOXORUBICIN HYDROCHLORIDE
Common Name English
(8S,10S)-10-((3-AMINO-2,3,6-TRIDEOXY-.ALPHA.-L-LYXO-HEXOPYRANOSYL)OXY)-8-GLYCOLOYL-7,8,9,10-TETRAHYDRO-6,8,11-TRIHYDROXY-1-METHOXY-5,12-NAPHTHACENEDIONE HYDROCHLORIDE
Common Name English
ADRIAMYCIN, HYDROCHLORIDE
Common Name English
DOXORUBICIN HYDROCHLORIDE [ORANGE BOOK]
Common Name English
DOXORUBICIN HYDROCHLORIDE [USP-RS]
Common Name English
Doxorubicin hydrochloride [WHO-DD]
Common Name English
DOXORUBICIN HYDROCHLORIDE [EMA EPAR]
Common Name English
CAELYX
Brand Name English
DOXORUBICIN HYDROCHLORIDE LIPOSOME [VANDF]
Common Name English
DOXORUBICINI HYDROCHLORIDUM [WHO-IP LATIN]
Common Name English
DOXORUBICIN HYDROCHLORIDE [MART.]
Common Name English
DOXIL
Brand Name English
DOXORUBICIN HYDROCHLORIDE [EP MONOGRAPH]
Common Name English
DOXORUBICIN HYDROCHLORIDE [USP MONOGRAPH]
Common Name English
HYDROXYDAUNOMYCIN HYDROCHLORIDE
Common Name English
DOXORUBICIN HCL
Common Name English
DOXORUBICIN HYDROCHLORIDE [VANDF]
Common Name English
DOXORUBICIN HYDROCHLORIDE [WHO-IP]
Common Name English
ADRIAMYCIN
Brand Name English
DOXORUBICIN HYDROCHLORIDE LIPOSOME
VANDF  
Common Name English
ADRIABLASTINA CS
Common Name English
ADRIAMYCIN [IARC]
Common Name English
RUBEX
Brand Name English
5,12-NAPHTHACENEDIONE, 10-((3-AMINO-2,3,6-TRIDEOXY-.ALPHA.-L-LYXO-HEXOPYRANOSYL)OXY)-7,8,9,10-TETRAHYDRO-6,8,11-TRIHYDROXY-8-(HYDROXYLACETYL)-1-METHOXY-, HYDROCHLORIDE (8S-CIS)-
Common Name English
Liposomal doxorubicin hydrochloride [WHO-DD]
Common Name English
DOXORUBICIN LIPOSOMAL COMPLEX OF THE HYDROCHLORIDE [MI]
Common Name English
DOXORUBICIN HYDROCHLORIDE [JAN]
Common Name English
Classification Tree Code System Code
EU-Orphan Drug EU/3/10/833
Created by admin on Fri Dec 15 15:19:48 UTC 2023 , Edited by admin on Fri Dec 15 15:19:48 UTC 2023
NCI_THESAURUS C67502
Created by admin on Fri Dec 15 15:19:48 UTC 2023 , Edited by admin on Fri Dec 15 15:19:48 UTC 2023
EMA ASSESSMENT REPORTS CAELYX (AUTHORIZED: MULTIPLE MYELOMA)
Created by admin on Fri Dec 15 15:19:48 UTC 2023 , Edited by admin on Fri Dec 15 15:19:48 UTC 2023
EMA ASSESSMENT REPORTS CAELYX (AUTHORIZED: OVARIAN NEOPLASMS)
Created by admin on Fri Dec 15 15:19:48 UTC 2023 , Edited by admin on Fri Dec 15 15:19:48 UTC 2023
EMA ASSESSMENT REPORTS MYOCET (AUTHORIZED: BREAST NEOLPLASMA)
Created by admin on Fri Dec 15 15:19:48 UTC 2023 , Edited by admin on Fri Dec 15 15:19:48 UTC 2023
FDA ORPHAN DRUG 229006
Created by admin on Fri Dec 15 15:19:48 UTC 2023 , Edited by admin on Fri Dec 15 15:19:48 UTC 2023
FDA ORPHAN DRUG 191704
Created by admin on Fri Dec 15 15:19:48 UTC 2023 , Edited by admin on Fri Dec 15 15:19:48 UTC 2023
FDA ORPHAN DRUG 210705
Created by admin on Fri Dec 15 15:19:48 UTC 2023 , Edited by admin on Fri Dec 15 15:19:48 UTC 2023
FDA ORPHAN DRUG 628318
Created by admin on Fri Dec 15 15:19:48 UTC 2023 , Edited by admin on Fri Dec 15 15:19:48 UTC 2023
FDA ORPHAN DRUG 311910
Created by admin on Fri Dec 15 15:19:48 UTC 2023 , Edited by admin on Fri Dec 15 15:19:48 UTC 2023
Code System Code Type Description
ECHA (EC/EINECS)
246-818-3
Created by admin on Fri Dec 15 15:19:48 UTC 2023 , Edited by admin on Fri Dec 15 15:19:48 UTC 2023
PRIMARY
FDA UNII
82F2G7BL4E
Created by admin on Fri Dec 15 15:19:48 UTC 2023 , Edited by admin on Fri Dec 15 15:19:48 UTC 2023
PRIMARY
CHEBI
28748
Created by admin on Fri Dec 15 15:19:48 UTC 2023 , Edited by admin on Fri Dec 15 15:19:48 UTC 2023
PRIMARY
MERCK INDEX
m4757
Created by admin on Fri Dec 15 15:19:48 UTC 2023 , Edited by admin on Fri Dec 15 15:19:48 UTC 2023
PRIMARY Merck Index
RXCUI
142433
Created by admin on Fri Dec 15 15:19:48 UTC 2023 , Edited by admin on Fri Dec 15 15:19:48 UTC 2023
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
DOXORUBICIN HYDROCHLORIDE
Created by admin on Fri Dec 15 15:19:48 UTC 2023 , Edited by admin on Fri Dec 15 15:19:48 UTC 2023
PRIMARY Description: A red-orange, crystalline powder. Solubility: Soluble in water and methanol R; practically insoluble in ether R. Category: Cytotoxic drug. Storage: Doxorubicin hydrochloride should be kept in a tightly closed container. Additional information: Doxorubicin hydrochloride is hygroscopic; it is poisonous: CAUTION: Doxorubicin hydrochloride must behandled with care, avoiding contact with the skin and inhalation of airborne particles. Definition. Doxorubicin hydrochloride contains not less than 97.0% and not more than 102.0% of C27H29NO11,HCl, calculatedwith reference to the anhydrous substance.
EVMPD
SUB06391MIG
Created by admin on Fri Dec 15 15:19:48 UTC 2023 , Edited by admin on Fri Dec 15 15:19:48 UTC 2023
PRIMARY
RS_ITEM_NUM
1225703
Created by admin on Fri Dec 15 15:19:48 UTC 2023 , Edited by admin on Fri Dec 15 15:19:48 UTC 2023
PRIMARY
DAILYMED
82F2G7BL4E
Created by admin on Fri Dec 15 15:19:48 UTC 2023 , Edited by admin on Fri Dec 15 15:19:48 UTC 2023
PRIMARY
CAS
25316-40-9
Created by admin on Fri Dec 15 15:19:48 UTC 2023 , Edited by admin on Fri Dec 15 15:19:48 UTC 2023
PRIMARY
PUBCHEM
443939
Created by admin on Fri Dec 15 15:19:48 UTC 2023 , Edited by admin on Fri Dec 15 15:19:48 UTC 2023
PRIMARY
ChEMBL
CHEMBL53463
Created by admin on Fri Dec 15 15:19:48 UTC 2023 , Edited by admin on Fri Dec 15 15:19:48 UTC 2023
PRIMARY
NCI_THESAURUS
C1326
Created by admin on Fri Dec 15 15:19:48 UTC 2023 , Edited by admin on Fri Dec 15 15:19:48 UTC 2023
PRIMARY
RXCUI
466523
Created by admin on Fri Dec 15 15:19:48 UTC 2023 , Edited by admin on Fri Dec 15 15:19:48 UTC 2023
ALTERNATIVE
EVMPD
SUB01827MIG
Created by admin on Fri Dec 15 15:19:48 UTC 2023 , Edited by admin on Fri Dec 15 15:19:48 UTC 2023
PRIMARY
EVMPD
SUB126795
Created by admin on Fri Dec 15 15:19:48 UTC 2023 , Edited by admin on Fri Dec 15 15:19:48 UTC 2023
ALTERNATIVE
DRUG BANK
DBSALT000060
Created by admin on Fri Dec 15 15:19:48 UTC 2023 , Edited by admin on Fri Dec 15 15:19:48 UTC 2023
PRIMARY
EPA CompTox
DTXSID3030636
Created by admin on Fri Dec 15 15:19:48 UTC 2023 , Edited by admin on Fri Dec 15 15:19:48 UTC 2023
PRIMARY
SMS_ID
100000089971
Created by admin on Fri Dec 15 15:19:48 UTC 2023 , Edited by admin on Fri Dec 15 15:19:48 UTC 2023
PRIMARY
Related Record Type Details
Structure of DOXORUBICIN
PARENT -> SALT/SOLVATE
Related Record Type Details
Structure of Acetone
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (GC)
USP
Structure of DOXORUBICINONE
IMPURITY -> PARENT
Structure of DAUNOMYCINONE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of DAUNORUBICIN
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Related Record Type Details
Structure of DOXORUBICIN
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966